Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Next Previous
X
Search
Trial Profile

A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms T3MPO-2
  • Sponsors Ardelyx

    • Most Recent Events

    • 09 Oct 2024 According to an Ardelyx media release, the company has recently published a review article in Clinical and Experimental Gastroenterology, an international, peer reviewed, open access journal. Data from the T3MPO-1 and T3MPO-2 studies are included within the review.
    • 21 May 2024 According to an Ardelyx media release, post-hoc pooled results from T3MPO-1 and T3MPO-2 trials were presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C.
    • 23 Oct 2023 According to Ardelyx media release, data from this study presented at the American College of Gastroenterology (ACG) annual meeting,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top